In this episode of JACC Deep Dive, Dr. Harlan Krumholz explores new insights from a post hoc analysis of the MASTER DAPT trial, highlighting the real-world burden of ischemic and bleeding events in high bleeding risk patients after PCI. By examining recurrent—not just first—events, the study sheds light on how abbreviated dual antiplatelet therapy (DAPT) impacts total clinical outcomes. Key findings include reduced bleeding without increased ischemic risk and a notable clustering of ischemic events following bleeding. This analysis advances the conversation around patient-centered endpoints and the evolving science of recurrent event modeling in cardiology.

Designing, enrolling in and completing randomized clinical trials in the cardiac intensive care unit (CICU) are fraught with challenges that hinder progress in advancing patient care. Low recruitment ...

Monotherapy with a P2Y12 inhibitor after a minimum period of dual antiplatelet therapy is an emerging approach to reduce the risk of bleeding after percutaneous coronary intervention (PCI). In a do...

This study evaluates the effectiveness and safety of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction in clinical practice.

Right ventricular reserve (RVR) describes the ability of the RV to augment cardiac output via contractile or diastolic reserve under stress, providing valuable insight into latent RV dysfunction acros...

Read about the life and achievements of Dr Victor Chang - a pioneer of heart transplant surgery and an Australian hero.